Structure Therapeutics Statistics
Total Valuation
GPCR has a market cap or net worth of $1.30 billion. The enterprise value is $450.90 million.
Important Dates
The last earnings date was Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GPCR has 57.54 million shares outstanding. The number of shares has increased by 30.50% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 57.54M |
| Shares Change (YoY) | +30.50% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 5.80% |
| Owned by Institutions (%) | 94.17% |
| Float | 48.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.53 |
| P/TBV Ratio | 1.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.29, with a Debt / Equity ratio of 0.01.
| Current Ratio | 23.29 |
| Quick Ratio | 22.94 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -22.85% and return on invested capital (ROIC) is -18.01%.
| Return on Equity (ROE) | -22.85% |
| Return on Assets (ROA) | -17.24% |
| Return on Invested Capital (ROIC) | -18.01% |
| Return on Capital Employed (ROCE) | -21.99% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$879,282 |
| Employee Count | 163 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GPCR has paid $379,000 in taxes.
| Income Tax | 379,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.81% in the last 52 weeks. The beta is -1.97, so GPCR's price volatility has been lower than the market average.
| Beta (5Y) | -1.97 |
| 52-Week Price Change | -57.81% |
| 50-Day Moving Average | 21.91 |
| 200-Day Moving Average | 29.83 |
| Relative Strength Index (RSI) | 43.19 |
| Average Volume (20 Days) | 725,532 |
Short Selling Information
| Short Interest | 9.32M |
| Short Previous Month | 9.14M |
| Short % of Shares Out | 16.20% |
| Short % of Float | 19.12% |
| Short Ratio (days to cover) | 8.30 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -182.52M |
| Pretax Income | -100.26M |
| Net Income | -143.32M |
| EBITDA | -181.48M |
| EBIT | -182.52M |
| Earnings Per Share (EPS) | -$2.59 |
Full Income StatementBalance Sheet
The company has $836.88 million in cash and $7.59 million in debt, giving a net cash position of $829.30 million or $14.41 per share.
| Cash & Cash Equivalents | 836.88M |
| Total Debt | 7.59M |
| Net Cash | 829.30M |
| Net Cash Per Share | $14.41 |
| Equity (Book Value) | 824.64M |
| Book Value Per Share | 14.33 |
| Working Capital | 813.14M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$134.79 million and capital expenditures -$1.44 million, giving a free cash flow of -$136.23 million.
| Operating Cash Flow | -134.79M |
| Capital Expenditures | -1.44M |
| Free Cash Flow | -136.23M |
| FCF Per Share | -$2.37 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |